Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Insight Molecular Diagnostics Q3 2026 Results: Net Loss of $3.58M, Loss Narrows

Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.60.3
Gross profit0.40.1
Net income-3.6-10.9
EPS (diluted, $ a share)$-0.10$-0.34

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+115.0%
Gross margin75.1%
Source

10-Q filed with the SEC, NASDAQ: IMDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Insight Molecular Diagnostics Inc.: key numbers

Share price
$1.86Close, Nov 16
Market cap
$60.9M
Shares outstanding
32.76MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Insight Molecular Diagnostics Inc.

All →
4:09 PM ET 8-K
Financial Results

Insight Molecular Diagnostics Financial Results

Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.

Term
Q3 2026
4:06 PM ET 8-K
M&A Deal

Insight Molecular Diagnostics M&A Deal with Chronix Biomedical, Inc.

Insight Molecular Diagnostics (iMDx) entered into Amendment No. 2 to its merger agreement with Chronix, modifying the earnout structure related to the CNI Monitor technology. The amendment establishes that equity holders will receive a 10% royalty on sales until a potential sale of the technology occurs, at which point they will receive a final payment of 10% of the gross sale proceeds.

Counterparty
Chronix Biomedical, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.